The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer

Neoplasia

Volumn 8, Issue 1, 2006, Pages 1-8

  Klein, Patrick J ^a,b,e   Schmidt, C Max ^a,b,c   Wiesenauer, Chad A ^a   Choi, Jennifer N ^a   Gage, Earl A ^a   Yip Schneider, Michele T ^a   Wiebke, Eric A ^a,b   Wang, Yufang ^a   Omer, Charles ^d   Sebolt Leopold, Judith S ^d  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

^e Building R4   (United States)

Author keywords

ERK; Hepatocellular carcinoma; Liver cancer; MEK; PD184161

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; PD 184161; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 33646398593     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05373     Document Type: Article

References (58)

1. Bosch FX, Ribes J, Cleries R, and Diaz M (2005). Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9, 191-211.
2. Llovet JM, Burroughs A, and Bruix J (2003). Hepatocellular carcinoma. Lancet 362, 1907-1917.
3. Olthoff KM (1998). Surgical options for hepatocellular carcinoma: resection and transplantation. Liver Transplant Surg 4, S98-S104.
4. Llovet JM (2005). Updated treatment approach to hepatocellular carcinoma. noma. J Gastroenterol 40, 225-235.
5. Coleman WB (2003). Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3, 573-588.
6. Romeo R and Colombo M (2002). The natural history of hepatocellular carcinoma. Toxicology 181-182, 39-42.
7. Feo F, Pascale RM, Simile MM, De Miglio MR, Muroni MR, and Calvisi D (2000). Genetic alterations in liver carcinogenesis: implications for new preventive and therapeutic strategies. Crit Rev Oncog 11, 19-62.
8. Cobb MH (1999). MAP kinase pathways. Prog Biophys Mol Biol 71, 479-500.
9. Rossomando AJ, Sanghera JS, Marsden LA, Weber MJ, Pelech SL, and Sturgill TW (1991). Biochemical characterization of a family of serine/threonine protein kinases regulated by tyrosine and serine/threonine phosphorylations. J Biol Chem 266, 20270-20275.
10. Mitra G, Weber M, and Stacey D (1993). Multiple pathways for activation of MAP kinases. Cell Mol Biol Res 39, 517-523.
11. Lenormand P, Pages G, Sardet C, L'Allemain G, Meloche S, and Pouyssegur J (1993). MAP kinases: activation, subcellular localization and role in the control of cell proliferation. Adv Second Messenger Phosphoprot Res 28, 237-244.
12. Lenormand P, Brondello JM, Brunet A, and Pouyssegur J (1998). Growth factor-induced p42/p44 MAPK nuclear translocation and retention requires both MAPK activation and neosynthesis of nuclear anchoring proteins. J Cell Biol 142, 625-633.
13. Wada T and Penninger JM (2004). Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23, 2838-2849.
14. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, and Ahn NG (1994). Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966-970.
15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
16. Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M, Matsuda Y, Nomoto M, and Aoyagi Y (2004). Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int 24, 432-436.
17. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, and Tran E (2003). Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3, 19.
18. Schmidt CM, McKillop IH, Cahill PA, and Sitzmann JV (1999). The role of cAMP-MAPK signalling in the regulation of human hepatocellular carcinoma growth in vitro vitro. Eur J Gastroenterol Hepatol 11, 1393-1399.
19. Schmidt CM, McKillop IH, Cahill PA, and Sitzmann JV (1997). Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 236, 54-58.
20. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, Ueki T, Hirano T, Yamamoto H, Fujimoto J, et al. (1998). Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27, 951-958.
21. McKillop IH, Schmidt CM, Cahill PA, and Sitzmann JV (1999). Inhibitory guanine nucleotide regulatory protein activation of mitogen-activated protein kinase in experimental hepatocellular carcinoma in vitro. Eur J Gastroenterol Hepatol 11, 761-768.
22. McKillop IH, Vyas N, Schmidt CM, Cahill PA, and Sitzmann JV (1999). Enhanced Gi-protein-mediated mitogenesis following chronic ethanol exposure in a rat model of experimental hepatocellular carcinoma. Hepatology 29, 412-420.
23. McKillop IH, Schmidt CM, Cahill PA, and Sitzmann JV (1999). Altered Gq/G11 guanine nucleotide regulatory protein expression in a rat model of hepatocellular carcinoma: role in mitogenesis. Hepatology 29, 371-378.
24. McKillop IH, Schmidt CM, Cahill PA, and Sitzmann JV (1997). Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology 26, 1484-1491.
25. Schmidt CM, McKillop IH, Cahill PA, and Sitzmann JV (1997). Alterations in guanine nucleotide regulatory protein expression and activity in human hepatocellular carcinoma. Hepatology 26, 1189-1194.
26. Schwarz M, Buchmann A, and Bock KW (1995). Role of cell proliferation at early stages of hepatocarcinogenesis. Toxicol Lett 82-83, 27-32.
27. Stahl S, Ittrich C, Marx-Stoelting P, Kohle C, Altug-Teber O, Riess O, Bonin M, Jobst J, Kaiser S, Buchmann A, et al. (2005). Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology 42, 353-361.
28. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, and Wittekind C (2003). Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52, 706-712.
29. Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS, Lee B, Bae SH, Kim J, and Park YM (2004). Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 29, 113-121.
30. Hopfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, and Scherubl H (2004). Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 41, 1008-1016.
31. Harada K, Shiota G, and Kawasaki H (1999). Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 19, 318-325.
32. Moon WS, Chang KJ, Majumdar AP, and Tarnawski AS (2004). Reduced expression of epidermal growth factor receptor-related protein in hepatocellular carcinoma: implications for cancer growth. Digestion 69, 219-224.
33. Tsutsumi T, Suzuki T, Moriya K, Shintani Y, Fujie H, Miyoshi H, Matsuura Y, Koike K, and Miyamura T (2003). Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 38, 820-828.
34. Fukuda K, Tsuchihara K, Hijikata M, Nishiguchi S, Kuroki T, and Shimotohno K (2001). Hepatitis C virus core protein enhances the activation of the transcription factor, Elk1, in response to mitogenic stimuli. Hepatology 33, 159-165.
35. Duesbery NS, Webb CP, and Vande Woude GF (1999). MEK wars, a new front in the battle against cancer. Nat Med 5, 736-737.
36. Milella M, Kornblau SM, and Andreeff M (2003). The mitogen-activated protein kinase signaling module as a therapeutic target in hematologic malignancies. Rev Clin Exp Hematol 7, 160-190.
37. Kohno M and Pouyssegur J (2003). Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Prog Cell Cycle Res 5, 219-224.
38. English JM and Cobb MH (2002). Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23, 40-45.
39. Wiesenauer CA, Yip-Schneider MT, Wang Y, and Schmidt CM (2004). Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg 198, 410-421.
40. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273, 18623-18632.
41. Alessi DR, Cuenda A, Cohen P, Dudley DT, and Saltiel AR (1995). PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270, 27489-27494.
42. Smalley KS (2003). A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104, 527-532.
43. Hilger RA, Scheulen ME, and Strumberg D (2002). The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25, 511-518.
44. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, and Yue W (2002). The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80, 239-256.
45. Seger R and Krebs EG (1995). The MAPK signaling cascade. FASEB J 9, 726-735.
46. Zhu J, Leng X, Dong N, Liu Y, Li G, and Du R (2002). Expression of mitogen-activated protein kinase and its upstream regulated signal in human hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi 40, 1-16.
47. Sebolt-Leopold JS (2000). Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19, 6594-6599.
48. Nottage M and Siu LL (2002). Rationale for Ras and raf-kinase as a target for cancer therapeutics. Curr Pharm Des 8, 2231-2242.
49. Marshall SJ, Senis YA, Auger JM, Feil R, Hofmann F, Salmon G, Peterson JT, Burslem F, and Watson SP(2004). GPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase. Blood 103 (7), 2601-2609.
50. Davies SP, Reddy H, Caivano M, and Cohen P (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351, 95-105.
51. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, et al. (2004). Multi-center phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22, 4456-4462.
52. Lorusso P, Krishnamurthi S, Rinehart JR, Nabell L, Croghan B, Varterasian M, Sadis SS, Menon SS, Leopold J, and Meyer MB (2005). A Phase 1-2 Clinical Study of a Second Generation Oral MEK Inhibitor, PD 0325901 in Patients with Advanced Cancer. American Society of Clinical Oncology, Orlando, FL.
53. Mitsui H, Takuwa N, Maruyama T, Maekawa H, Hirayama M, Sawatari T, Hashimoto N, Takuwa Y, and Kimura S (2001). The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int J Cancer 92, 55-62.
54. Duesbery NS, Resau J, Webb CP, Koochekpour S, Koo HM, Leppla SH, and Vande Woude GF (2001). Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci USA 98, 4089-4094.
55. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, et al. (1999). Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5, 810-816.
56. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, and Arteaga CL (2000). Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 60, 5887-5894.
57. Collisson EA, De A, Suzuki H, Gambhir SS, and Kolodney MS (2003). Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 63, 5669-5673.
58. Kramer BW, Gotz R, and Rapp UR (2004). Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. BMC Cancer 4, 24.